VYNE – VYNE Therapeutics Inc.
VYNE — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
0.6
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
-0.48
EPS This/Next Y
-0.55
Price
0.6
Target Price
2
Analyst Recom
2.33
Performance Q
1.49
Upside
-1,532.2%
Beta
1.91
Ticker: VYNE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | VYNE | 0.6011 | N/A | N/A | 0 |
| 2026-03-02 | VYNE | 0.6046 | N/A | N/A | 0 |
| 2026-03-03 | VYNE | 0.5892 | N/A | N/A | 0 |
| 2026-03-04 | VYNE | 0.5938 | N/A | N/A | 0 |
| 2026-03-05 | VYNE | 0.5821 | N/A | N/A | 0 |
| 2026-03-06 | VYNE | 0.5903 | N/A | N/A | 0 |
| 2026-03-09 | VYNE | 0.59 | N/A | N/A | 0 |
| 2026-03-10 | VYNE | 0.6031 | N/A | N/A | 0 |
| 2026-03-11 | VYNE | 0.6057 | N/A | N/A | 0 |
| 2026-03-12 | VYNE | 0.5887 | N/A | N/A | 0 |
| 2026-03-13 | VYNE | 0.5874 | N/A | N/A | 0 |
| 2026-03-17 | VYNE | 0.612 | N/A | N/A | 0 |
| 2026-03-18 | VYNE | 0.587 | N/A | N/A | 0 |
| 2026-03-19 | VYNE | 0.62 | N/A | N/A | 0 |
| 2026-03-20 | VYNE | 0.6179 | N/A | N/A | 0 |
| 2026-03-23 | VYNE | 0.6101 | N/A | N/A | 0 |
| 2026-03-24 | VYNE | 0.6082 | N/A | N/A | 0 |
| 2026-03-25 | VYNE | 0.623 | N/A | N/A | 0 |
| 2026-03-26 | VYNE | 0.6111 | N/A | N/A | 0 |
| 2026-03-27 | VYNE | 0.6 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | VYNE | 0.60 | - | - | -0.89 |
| 2026-03-02 | VYNE | 0.61 | - | - | -1.10 |
| 2026-03-03 | VYNE | 0.59 | - | - | -1.10 |
| 2026-03-04 | VYNE | 0.59 | - | - | -1.10 |
| 2026-03-05 | VYNE | 0.58 | - | - | -1.10 |
| 2026-03-06 | VYNE | 0.59 | - | - | -1.10 |
| 2026-03-09 | VYNE | 0.59 | - | - | -1.10 |
| 2026-03-10 | VYNE | 0.60 | - | - | -1.10 |
| 2026-03-11 | VYNE | 0.60 | - | - | -1.10 |
| 2026-03-12 | VYNE | 0.59 | - | - | -1.10 |
| 2026-03-13 | VYNE | 0.60 | - | - | -1.10 |
| 2026-03-17 | VYNE | 0.61 | - | - | -1.10 |
| 2026-03-18 | VYNE | 0.59 | - | - | -1.10 |
| 2026-03-19 | VYNE | 0.62 | - | - | -1.10 |
| 2026-03-20 | VYNE | 0.62 | - | - | -1.10 |
| 2026-03-23 | VYNE | 0.61 | - | - | -1.10 |
| 2026-03-24 | VYNE | 0.61 | - | - | -1.10 |
| 2026-03-25 | VYNE | 0.63 | - | - | -1.10 |
| 2026-03-26 | VYNE | 0.61 | - | - | -1.10 |
| 2026-03-27 | VYNE | 0.60 | - | - | -1.10 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | VYNE | 0.00 | 16.03 | 1.75 |
| 2026-03-02 | VYNE | 0.00 | 16.14 | 1.75 |
| 2026-03-03 | VYNE | 0.00 | 16.14 | 1.75 |
| 2026-03-04 | VYNE | 0.00 | 16.14 | 1.75 |
| 2026-03-05 | VYNE | 0.00 | 16.14 | 1.75 |
| 2026-03-06 | VYNE | 0.00 | 16.14 | 1.75 |
| 2026-03-09 | VYNE | 0.00 | 0 | 1.75 |
| 2026-03-10 | VYNE | 0.00 | 0 | 1.75 |
| 2026-03-11 | VYNE | 0.00 | 0 | 0.68 |
| 2026-03-12 | VYNE | 0.00 | 0 | 0.68 |
| 2026-03-13 | VYNE | 0.00 | 0 | 0.68 |
| 2026-03-17 | VYNE | 0.00 | 16.12 | 0.68 |
| 2026-03-18 | VYNE | 0.00 | 16.12 | 0.68 |
| 2026-03-19 | VYNE | 0.00 | 16.12 | 0.68 |
| 2026-03-20 | VYNE | 0.00 | 16.12 | 0.68 |
| 2026-03-23 | VYNE | 0.00 | 16.13 | 0.68 |
| 2026-03-24 | VYNE | 0.00 | 16.13 | 0.68 |
| 2026-03-25 | VYNE | 0.00 | 16.13 | 0.60 |
| 2026-03-26 | VYNE | 0.00 | 16.13 | 0.60 |
| 2026-03-27 | VYNE | 0.00 | 16.13 | 0.60 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.18
Avg. EPS Est. Next Quarter
-0.18
Insider Transactions
Institutional Transactions
16.13
Beta
1.91
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
20
Growth Score
28
Sentiment Score
45
Actual DrawDown %
99.5
Max Drawdown 5-Year %
-99.8
Target Price
2
P/E
Forward P/E
PEG
P/S
34.57
P/B
0.71
P/Free Cash Flow
EPS
-0.65
Average EPS Est. Cur. Y
-1.1
EPS Next Y. (Est.)
-1.65
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-4646.14
Relative Volume
0.34
Return on Equity vs Sector %
-122.7
Return on Equity vs Industry %
-106.5
EPS 1 7Days Diff
-1.1
EPS 1 30Days Diff
-1.1
EBIT Estimation
◆
VYNE
Healthcare
$0.59
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
47.9
Range 1M
60.7%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
7.9%
EPS NY
5.8%
52W%
19%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+239% upside
Upside
+239%
Quality
20
VYNE Therapeutics Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 10
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
VYNE
Latest News
—
Caricamento notizie per VYNE…
stock quote shares VYNE – VYNE Therapeutics Inc. Stock Price stock today
news today VYNE – VYNE Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VYNE – VYNE Therapeutics Inc. yahoo finance google finance
stock history VYNE – VYNE Therapeutics Inc. invest stock market
stock prices VYNE premarket after hours
ticker VYNE fair value insiders trading